clinical trial · NCT05256381
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Non-Small Cell Lung CancerColorectal CancerCutaneous Squamous Cell CarcinomaHepatocellular CarcinomaCastration-resistant Prostate CancerOvarian CancerNanrilkefusp AlfaPembrolizumab
brief summary
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
started
Jun 21, 2022
primary completion
Aug 31, 2024
completion
Nov 29, 2024
last updated
Nov 17, 2025
official title
A Phase 2, Open-label, Single-arm, Multicenter Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced/Refractory Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol